Macrogenics Inc (MGNX)

Schlusskurs vom Vortag:

$15.22

Offen:

$15.64

24-Stunden-Volumen:

610.62K

Marktkapitalisierung:

$980.32M

Einnahmen:

$56.91M

Nettoeinkommen (Verlust:

$-9.06M

KGV:

130.58

EPS:

0.12

Netto-Cashflow:

$-79.97M

1W Leistung:

+7.62%

1M Leistung:

+14.63%

6M Leistung:

+195.10%

1J Leistung:

+127.43%

1-Tages-Spanne:

$15.32

$16.14

52-Wochen-Spanne:

$4.29

$21.88

Macrogenics Inc Stock (MGNX) Company Profile

Firmenname

Macrogenics Inc

Sektor

Healthcare (1213)

Branche

Biotechnology (699)

Telefon

301-251-5172

Adresse

9704 Medical Center Drive, Rockville, MD

Mitarbeiter

330

Twitter

@macrogenics

Nächster Verdiensttermin

2024-05-09

Neueste SEC-Einreichungen

MGNX's Discussions on Twitter

Macrogenics Inc Stock (MGNX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-12-20	Hochstufung	Citigroup	Neutral → Buy
2023-11-07	Hochstufung	Guggenheim	Neutral → Buy
2023-03-17	Herabstufung	Guggenheim	Buy → Neutral
2022-11-22	Herabstufung	Cowen	Outperform → Market Perform
2022-11-14	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2022-07-18	Herabstufung	SMBC Nikko	Outperform → Neutral
2022-07-11	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2022-05-04	Herabstufung	Guggenheim	Buy → Neutral
2022-02-28	Hochstufung	Citigroup	Neutral → Buy
2022-02-11	Eingeleitet	BMO Capital Markets	Outperform
2022-02-04	Eingeleitet	SMBC Nikko	Outperform
2021-11-17	Fortgesetzt	Guggenheim	Buy
2021-10-19	Eingeleitet	JMP Securities	Mkt Outperform
2021-10-15	Fortgesetzt	BTIG Research	Buy
2021-04-26	Fortgesetzt	Credit Suisse	Outperform
2021-03-12	Hochstufung	Barclays	Underweight → Overweight
2020-12-22	Fortgesetzt	H.C. Wainwright	Buy
2020-08-03	Herabstufung	Citigroup	Buy → Neutral
2020-06-01	Hochstufung	Guggenheim	Neutral → Buy
2020-05-26	Bestätigt	H.C. Wainwright	Buy
2020-03-04	Eingeleitet	Barclays	Underweight
2019-12-19	Eingeleitet	Cantor Fitzgerald	Overweight
2019-12-18	Eingeleitet	Cantor Fitzgerald	Overweight
2019-11-21	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2019-11-20	Fortgesetzt	Guggenheim	Neutral
2019-05-03	Hochstufung	Wedbush	Neutral → Outperform
2019-04-12	Eingeleitet	Guggenheim	Neutral
2019-02-07	Hochstufung	Citigroup	Sell → Buy
2019-02-07	Herabstufung	Wedbush	Outperform → Neutral
2019-02-06	Hochstufung	Raymond James	Underperform → Mkt Perform
2019-02-04	Herabstufung	Citigroup	Neutral → Sell
2018-12-10	Herabstufung	Raymond James	Outperform → Underperform
2018-09-10	Fortgesetzt	BTIG Research	Buy
2018-05-31	Eingeleitet	Evercore ISI	Outperform
2018-03-05	Eingeleitet	H.C. Wainwright	Buy
2017-03-31	Eingeleitet	Raymond James	Outperform

Alle ansehen

Macrogenics Inc Aktie (MGNX) Neueste Nachrichten

MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call

GlobeNewswire Inc.

MacroGenics Analyst Impressed By Improved Safety Profile From Prostate Cancer Candidate

Benzinga

Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

The Latest Analyst Ratings For Macrogenics

Benzinga

Simulations Plus Posts Upbeat, Joins Levi Strauss, BlackBerry And Other Big Stocks Moving Higher In Thursday's Pre-Market Session

Benzinga

MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

GlobeNewswire Inc.

Finanzdaten der Macrogenics Inc-Aktie (MGNX)

Macrogenics Inc (MGNX) Umsatz 2024

Macrogenics Inc (MGNX) Nettogewinn 2024

Macrogenics Inc (MGNX) Free Cashflow 2024

Macrogenics Inc (MGNX) Gewinn je Aktie 2024